TY - JOUR AU - Sonpavde, G. AU - Hutson, T. E. PY - 2007 DA - 2007// TI - Pazopanib: a novel multitargeted tyrosine kinase inhibitor JO - Curr Oncol Rep VL - 9 UR - https://doi.org/10.1007/s11912-007-0007-2 DO - 10.1007/s11912-007-0007-2 ID - Sonpavde2007 ER - TY - JOUR AU - Sternberg, C. N. AU - Hawkins, R. E. AU - Wagstaff, J. AU - Salman, P. AU - Mardiak, J. AU - Barrios, C. H. PY - 2013 DA - 2013// TI - A randomised, double-blind phase III study of pazopanib in patients with advanced and/or metastatic renal cell carcinoma: final overall survival results and safety update JO - Eur J Cancer VL - 49 UR - https://doi.org/10.1016/j.ejca.2012.12.010 DO - 10.1016/j.ejca.2012.12.010 ID - Sternberg2013 ER - TY - JOUR AU - Land, J. D. AU - Chen, A. H. AU - Atkinson, B. J. AU - Cauley, D. H. AU - Tannir, N. M. PY - 2016 DA - 2016// TI - Proteinuria with first-line therapy of metastatic renal cell cancer JO - J Oncol Pham Pract VL - 22 UR - https://doi.org/10.1177/1078155214563153 DO - 10.1177/1078155214563153 ID - Land2016 ER - TY - STD TI - eHealthMe.com. Mountain View, CA. Votrient and Nephrotic syndrome - from FDA reports. http://www.ehealthme.com/ds/votrient/nephrotic-syndrome/. Accessed 24 Nov 2017. UR - http://www.ehealthme.com/ds/votrient/nephrotic-syndrome/ ID - ref4 ER - TY - JOUR AU - Nolasco, F. AU - Cameron, J. S. AU - Heywood, E. F. AU - Hicks, J. AU - Ogg, C. AU - Williams, D. G. PY - 1986 DA - 1986// TI - Adult-onset minimal change nephrotic syndrome: a long-term follow-up JO - Kidney Int VL - 29 UR - https://doi.org/10.1038/ki.1986.130 DO - 10.1038/ki.1986.130 ID - Nolasco1986 ER - TY - JOUR AU - Izzedine, H. AU - Massard, C. AU - Spano, J. P. AU - Goldwasser, F. AU - Khayat, D. AU - Soria, J. C. PY - 2010 DA - 2010// TI - VEGF signalling inhibition-induced proteinuria: mechanisms, significance and management JO - Eur J Cancer VL - 46 UR - https://doi.org/10.1016/j.ejca.2009.11.001 DO - 10.1016/j.ejca.2009.11.001 ID - Izzedine2010 ER - TY - JOUR AU - Izzedine, H. AU - Rixe, O. AU - Billemont, B. AU - Baumelou, A. AU - Deray, G. PY - 2007 DA - 2007// TI - Angiogenesis inhibitor therapies: focus on kidney toxicity and hypertension JO - Am J Kidney Dis VL - 50 UR - https://doi.org/10.1053/j.ajkd.2007.04.025 DO - 10.1053/j.ajkd.2007.04.025 ID - Izzedine2007 ER - TY - JOUR AU - Ollero, M. AU - Sahali, D. PY - 2015 DA - 2015// TI - Inhibition of the VEGF signalling pathway and glomerular disorders JO - Nephrol Dial Transplant VL - 30 UR - https://doi.org/10.1093/ndt/gfu368 DO - 10.1093/ndt/gfu368 ID - Ollero2015 ER - TY - STD TI - American Cancer Society. Survival Rates for Kidney Cancer by Stage. https://www.cancer.org/cancer/kidney-cancer/detection-diagnosis-staging/survival-rates.html (2017). Accessed 29 Nov 2017. UR - https://www.cancer.org/cancer/kidney-cancer/detection-diagnosis-staging/survival-rates.html ID - ref9 ER - TY - JOUR AU - Xie, M. AU - He, C. S. AU - Huang, J. K. AU - Lin, Q. Z. PY - 2015 DA - 2015// TI - Phase II study of pazopanib as second-line treatment after sunitinib in patients with metastatic renal cell carcinoma: a southern China urology Cancer consortium trial JO - Eur J Cancer VL - 51 UR - https://doi.org/10.1016/j.ejca.2015.01.005 DO - 10.1016/j.ejca.2015.01.005 ID - Xie2015 ER - TY - JOUR AU - Cosmai, L. AU - Gallieni, M. AU - Liguigli, W. AU - Porta, C. PY - 2017 DA - 2017// TI - Renal toxicity of anticancer agents targeting vascular endothelial growth factor (VEGF) and its receptors (VEGFRs) JO - J Nephrol VL - 30 UR - https://doi.org/10.1007/s40620-016-0311-8 DO - 10.1007/s40620-016-0311-8 ID - Cosmai2017 ER -